{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:22:26Z","timestamp":1791969746760,"version":"4.3.4"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown notable advancements in managing blood sugar control. Nevertheless, there remains a gap in real-world data regarding the variation in acute pancreatitis (AP) risk among different GLP-1 RAs. Our study aimed to characterize and evaluate AP associated with different GLP-1 RAs (exenatide, lixisenatide, liraglutide, albiglutide, semaglutide, dulaglutide and tirzepatide) in a public adverse events database and to review the relevant case reports.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We described a case series of patients experiencing AP while on GLP-1 RAs. Additionally, we utilized various algorithms including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS) to analyze data from the Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS) regarding suspected adverse events of AP linked to GLP-1 RAs from January 2005 to September 2023.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our case series comprised thirty-nine patients who experienced AP events while on GLP-1 RAs. Within the FAERS database, we retrieved a total of 6,751 individual case safety reports (ICSRs) involving various GLP-1 RAs. The median age of the patients included in our study was 57 years (range: 14\u201399), with 98.3% of cases classified as serious. Signals indicating AP were observed across all GLP-1 RAs, with particular emphasis on exenatide and liraglutide.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>There is a notable reporting signal of AP associated with all GLP-1 RAs. Healthcare providers must remain vigilant and closely monitor this potentially life-threatening adverse event.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1461398","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T11:56:58Z","timestamp":1731499018000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":33,"title":["Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Hui","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"A388","DOI":"10.1210\/jendso\/bvac150.808","article-title":"PSUN241 A case of dulaglutide-induced acute pancreatitis in a diabetic patient \u2013 a case report","volume":"6","author":"Abdelmasih","year":"2022","journal-title":"J. Endocr. Soc."},{"key":"B2","article-title":"FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes","author":"Administration","year":"2013","journal-title":"Drug Safe. Avai."},{"key":"B3","doi-asserted-by":"publisher","first-page":"875","DOI":"10.2165\/00002018-200629100-00005","article-title":"Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department","volume":"29","author":"Almenoff","year":"2006","journal-title":"Drug Saf."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e21616","DOI":"10.7759\/cureus.21616","article-title":"Liraglutide overdose-induced acute pancreatitis","volume":"14","author":"Alsaadoun","year":"2022","journal-title":"Cureus"},{"key":"B5","doi-asserted-by":"publisher","first-page":"S768","DOI":"10.14309\/01.ajg.0000595080.14595.de","article-title":"1388 Dose increment-associated liraglutide-induced acute pancreatitis","volume":"114","author":"Al-Salameh","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4158\/EP09104.CRR","article-title":"Exenatide-induced acute pancreatitis","volume":"16","author":"Ayoub","year":"2010","journal-title":"Endocr. Pract."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e20938","DOI":"10.7759\/cureus.20938","article-title":"Case report of acute pancreatitis associated with combination treatment of dulaglutide and glipizide","volume":"14","author":"Babajide","year":"2022","journal-title":"Cureus"},{"key":"B8","first-page":"581","article-title":"Drug-induced acute pancreatitis in a cohort of 328 patients. A single-centre experience from Australia","volume":"12","author":"Barreto","year":"2011","journal-title":"Jop"},{"key":"B9","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"A393","DOI":"10.1210\/jendso\/bvab048.800","article-title":"Necrotizing pancreatitis secondary to dulaglutide use","volume":"5","author":"Bhat","year":"2021","journal-title":"J. Endocr. Soc."},{"key":"B11","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2515\/therapie\/2012076","article-title":"Late and severe acute necrotizing pancreatitis in a patient with liraglutide","volume":"67","author":"Bourezane","year":"2012","journal-title":"Therapie"},{"key":"B12","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s12020-020-02223-6","article-title":"GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials","volume":"68","author":"Cao","year":"2020","journal-title":"Endocrine"},{"key":"B13","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s11096-023-01556-2","article-title":"Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis","volume":"45","author":"Cao","year":"2023","journal-title":"Int. J. Clin. Pharm."},{"key":"B14","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.eprac.2023.03.034","article-title":"Abstract #1402779: a case of possible tirzepatide-induced pancreatitis","volume":"29","author":"Casanovas","year":"2023","journal-title":"Endocr. Pract."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.pan.2020.07.401","article-title":"Drug-induced acute pancreatitis: prevalence, causative agents, and outcomes","volume":"20","author":"Chadalavada","year":"2020","journal-title":"Pancreatology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"6576","DOI":"10.1002\/cam4.3198","article-title":"Renal adverse effects following the use of different immune checkpoint inhibitor regimens: a real-world pharmacoepidemiology study of post-marketing surveillance data","volume":"9","author":"Chen","year":"2020","journal-title":"Cancer Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/SGA.0000000000000602","article-title":"Acute pancreatitis and type 2 diabetes mellitus: glp-1 receptor agonist or idiopathic, a diagnostic dilemma, a case report with literature review","volume":"44","author":"Cheng","year":"2021","journal-title":"Gastroenterol. Nurs."},{"key":"B18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.15386\/cjmed-804","article-title":"Acute pancreatitis during GLP-1 receptor agonist treatment. A case report","volume":"91","author":"Chis","year":"2018","journal-title":"Clujul Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13098-023-01086-x","article-title":"Association between glycemic status and the risk of acute pancreatitis: a nationwide population-based study","volume":"15","author":"Cho","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"key":"B20","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.dsx.2021.03.010","article-title":"Early onset of acute pancreatitis in a patient on low-dose liraglutide","volume":"15","author":"Chua","year":"2021","journal-title":"Diabetes Metab. Syndr."},{"key":"B22","doi-asserted-by":"publisher","first-page":"471","DOI":"10.2337\/diacare.29.02.06.dc05-2043","article-title":"Exenatide (exendin-4)-induced pancreatitis: a case report","volume":"29","author":"Denker","year":"2006","journal-title":"Diabetes Care"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e00380","DOI":"10.14309\/crj.0000000000000380","article-title":"Liraglutide-induced hemorrhagic pancreatitis in a nondiabetic patient","volume":"7","author":"Dolan","year":"2020","journal-title":"ACG Case Rep. J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"Dumouchel","year":"1999","journal-title":"Am. Stat."},{"key":"B26","doi-asserted-by":"publisher","first-page":"314","DOI":"10.4103\/jod.jod_78_22","article-title":"Serious adverse effects following use of liraglutide in individuals with type 2 diabetes","volume":"13","author":"Easow","year":"2022","journal-title":"J. Diabetol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"S1470","DOI":"10.14309\/01.ajg.0000957636.56371.78","article-title":"S1999 -The dark side of semaglutide discrete instances of acalculous cholecystitis and acute pancreatitis in the same patient due to continued use of GLP-1 agonist","volume":"118","author":"Ebiai","year":"2023","journal-title":"Am. J. Gastroenterol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B30","doi-asserted-by":"publisher","first-page":"540","DOI":"10.6092\/1590-8577\/1107","article-title":"Pancreatitis during treatment with liraglutide","volume":"13","author":"Famularo","year":"2012","journal-title":"J. Pancreas"},{"key":"B31","article-title":"Liraglutide induced acute pancreatitis and jaundice in an elderly female \u2013 case report","volume":"9","author":"Farooqui","year":"2019","journal-title":"World J. Res. Rev."},{"key":"B32","doi-asserted-by":"publisher","first-page":"S728","DOI":"10.14309\/01.ajg.0000594772.87672.64","article-title":"1311 Acute pancreatitis in a patient using liraglutide for weight loss","volume":"114","author":"Fatakhova","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"S736","DOI":"10.14309\/01.ajg.0000780092.28084.14","article-title":"S1640 Necrotizing pancreatitis associated with liraglutide and empagliflozin","volume":"116","author":"Fernandez","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1345\/aph.1Q789","article-title":"Pancreatitis: a potential complication of liraglutide?","volume":"46","author":"Franks","year":"2012","journal-title":"Ann. Pharmacother."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1516493","DOI":"10.1155\/2020\/1516493","article-title":"A drug-induced acute pancreatitis retrospective study","volume":"2020","author":"Gagnon","year":"2020","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s43162-020-00026-9","article-title":"Mildly symptomatic liraglutide-induced acute pancreatitis in a patient with type 2 diabetes mellitus: a case report","volume":"32","author":"Gameil","year":"2020","journal-title":"Egypt J. Intern Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","first-page":"S769","DOI":"10.14309\/00000434-201810001-01342","article-title":"Liraglutide associated acute pancreatitis: a case report and review of the literature: 1342","volume":"113","author":"Ghabra","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/j.1463-1326.2010.01231.x","article-title":"Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes","volume":"12","author":"Girman","year":"2010","journal-title":"Diabetes Obes. Metab."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.4158\/EP11264.CR","article-title":"Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide","volume":"18","author":"Iyer","year":"2012","journal-title":"Endocr. Pract."},{"key":"B44","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1177\/2042098616667352","article-title":"Albiglutide-induced pancreatitis","volume":"7","author":"Jain","year":"2016","journal-title":"Ther. Adv. Drug Saf."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e38263","DOI":"10.7759\/cureus.38263","article-title":"Liraglutide-induced pancreatitis: a case report and literature review","volume":"15","author":"Javed","year":"2023","journal-title":"Cureus"},{"key":"B46","first-page":"64","article-title":"Liraglutide-induced acute pancreatitis","volume":"62","author":"Jeyaraj","year":"2014","journal-title":"J. Assoc. Physicians India"},{"key":"B47","first-page":"45","article-title":"Drug-induced acute pancreatitis: a review","volume":"15","author":"Jones","year":"2015","journal-title":"Ochsner J."},{"key":"B48","first-page":"349","article-title":"Drug-induced pancreatitis: a potentially serious and underreported problem","volume":"38","author":"Kaufman","year":"2013","journal-title":"P t"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e38630","DOI":"10.7759\/cureus.38630","article-title":"Dulaglutide (trulicity)-induced acute pancreatitis: a case report","volume":"15","author":"Khan","year":"2023","journal-title":"Cureus"},{"key":"B50","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2146\/ajhp110221","article-title":"Liraglutide-associated acute pancreatitis","volume":"69","author":"Knezevich","year":"2012","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad114.875","article-title":"FRI657 Case series on GLP-1 receptor agonist related acute pancreatitis","volume":"7","author":"Kumar Kulkarni","year":"2023","journal-title":"J. Endocr. Soc."},{"key":"B52","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0140-6736(14)60649-8","article-title":"Acute pancreatitis","volume":"386","author":"Lankisch","year":"2015","journal-title":"Lancet"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1345\/aph.1P714","article-title":"Acute pancreatitis associated with liraglutide","volume":"45","author":"Lee","year":"2011","journal-title":"Ann. Pharmacother."},{"key":"B54","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41575-019-0158-2","article-title":"New insights into acute pancreatitis","volume":"16","author":"Lee","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/pds.1601","article-title":"A comparison of measures of disproportionality for signal detection on adverse drug reaction spontaneous reporting database of Guangdong province in China","volume":"17","author":"Li","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e50051","DOI":"10.7759\/cureus.50051","article-title":"An atypical presentation of dulaglutide-induced pancreatitis complicated by superior mesenteric vein thrombosis","volume":"15","author":"Manuel","year":"2023","journal-title":"Cureus"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"","journal-title":"N. Engl. J. Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/nejmoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"","journal-title":"N. Engl. J. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1159\/000092104","article-title":"Obesity is a definitive risk factor of severity and mortality in acute pancreatitis: an updated meta-analysis","volume":"6","author":"Mart\u00ednez","year":"2006","journal-title":"Pancreatology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)","volume":"44","author":"Marx","year":"2023","journal-title":"Eur. Heart J."},{"key":"B61","first-page":"465","article-title":"Predictors of in hospital mortality in acute pancreatitis","volume":"18","author":"Mossad","year":"2017","journal-title":"J. Pancreas"},{"key":"B62","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.2169\/internalmedicine.51.7876","article-title":"Pancreatitis with pancreatic tail swelling associated with incretin-based therapies detected radiologically in two cases of diabetic patients with end-stage renal disease","volume":"51","author":"Nakata","year":"2012","journal-title":"Intern Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"B64","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/dom.12591","article-title":"Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"18","author":"Nauck","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"B65","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/ccr3.83","article-title":"Sitagliptin-induced pancreatitis - a longer road than expected","volume":"2","author":"Nelson","year":"2014","journal-title":"Clin. Case Rep."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e39011","DOI":"10.7759\/cureus.39011","article-title":"Severe, complicated pancreatitis with an unclear etiology","volume":"15","author":"Nohomovich","year":"2023","journal-title":"Cureus"},{"key":"B67","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.2147\/DDDT.S81998","article-title":"Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases","volume":"9","author":"Nomura","year":"2015","journal-title":"Drug Des. Devel Ther."},{"key":"B68","doi-asserted-by":"publisher","first-page":"e43773","DOI":"10.7759\/cureus.43773","article-title":"Acute pancreatitis in a patient taking semaglutide","volume":"15","author":"Patel","year":"2023","journal-title":"Cureus"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"329","DOI":"10.17235\/reed.2018.5912\/2018","article-title":"Scientific report: a case of acute pancreatitis due to liraglutide","volume":"111","author":"Quesada-V\u00e1zquez","year":"2018","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"B71","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.diabres.2015.10.014","article-title":"Incretin-based therapies are associated with acute pancreatitis: meta-analysis of large randomized controlled trials","volume":"110","author":"Roshanov","year":"2015","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e40576","DOI":"10.7759\/cureus.40576","article-title":"First reported case of dulaglutide-induced acute pancreatitis with normal serum lipase level","volume":"15","author":"Shahbazi","year":"2023","journal-title":"Cureus"},{"key":"B73","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1080\/17512433.2020.1736041","article-title":"Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials","volume":"13","author":"Singh","year":"2020","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"e33853","DOI":"10.1097\/MD.0000000000033853","article-title":"Home monitoring vs hospitalization for mild acute pancreatitis. A pilot randomized controlled clinical trials","volume":"102","author":"Sorribas","year":"2023","journal-title":"Med. Baltim."},{"key":"B75","doi-asserted-by":"publisher","first-page":"S308","DOI":"10.14309\/00000434-201210001-00744","article-title":"Liraglutide-induced acute pancreatitis: 744","volume":"107","author":"Taunk","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"B76","first-page":"987","article-title":"Exenatide and acute pancreatitis","volume":"56","author":"Tripathy","year":"2008","journal-title":"J. Assoc. Physicians India"},{"key":"B77","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B78","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/00325481.2021.2002616","article-title":"Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice","volume":"134","author":"Wharton","year":"2022","journal-title":"Postgrad. Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"e0231883","DOI":"10.1371\/journal.pone.0231883","article-title":"Drug induced pancreatitis: a systematic review of case reports to determine potential drug associations","volume":"15","author":"Wolfe","year":"2020","journal-title":"PLoS One"},{"key":"B80","doi-asserted-by":"publisher","first-page":"A399","DOI":"10.1210\/jendso\/bvac150.831","article-title":"PSUN270 Magnified risk of pancreatitis by GLP-1: a case of necrotizing pancreatitis in a patient on dulaglutide with baseline elevated triglycerides","volume":"6","author":"Yau","year":"2022","journal-title":"J. Endocr. Soc."},{"key":"B81","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2147\/DMSO.S348025","article-title":"Difference in gastrointestinal risk associated with use of GLP-1 receptor agonists: a real-world pharmacovigilance study","volume":"15","author":"Zhou","year":"2022","journal-title":"Diabetes Metab. Syndr. Obes."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1461398\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T11:57:02Z","timestamp":1731499022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1461398\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":80,"alternative-id":["10.3389\/fphar.2024.1461398"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1461398","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]},"article-number":"1461398"}}